AIM-HIV PROJECT------------------------Instituto Salud Carlos III


Worldwide the majority of HIV infections are transmitted through sexual intercourse between men and women. Sexual transmission of HIV can be prevented by proper use of condoms and effective treatment of infected patients, which reduces viral load below the limit of detection reducing drastically the risk of transmission. However in many countries across the world access to prevention and treatment services is limited. Besides, in these countries women are particularly vulnerable because of social factors, gender inequalities and concomitant sexually transmitted infections. Diminishing HIV transmission among women is a key step towards undermine the virus presence since it will not be transmitted to the new generation of children and to their partners. Microbicides, compounds that can be applied inside the vagina (or rectum) to protect against HIV transmission, could be a potentially important preventive tool for these populations.

AIM-HIV is the acronym of “Anti-Inflammatory Microbicides against HIV”. It is a project funded by the 7th Framework Program (FP7) for Research and Technological Development of the European Community that is coordinated by Dr José Alcamí from Instituto de Salud Carlos III based in Madrid, Spain. The main objective of the AIM-HIV project is the development of a microbicide based on 5-Hydroxytyrosol. This molecule represents a new class of microbicides displaying both antiviral and anti-inflammatory properties that has shown promising preliminary results against HIV in vitro.

For this aim, we have created a consortium composed by a SME company with strong research and development capacities and broad experience in the field of hydroxytyrosol, SEPROX Biotech S.L., and three European research groups with a profound knowledge on HIV pathogenesis: Instituto de Salud Carlos III (ISCIII), Commissariat à l’énergie atomique et aux energies alternatives (CEA) and Università Vita-Salute San Raffaele (USR).

The final goal of the project is to provide an effective and low-cost new microbicide in order to reduce HIV infection in countries with high incidence of HIV transmission, with special attention to sub-Saharan Africa. To this aim the consortium has already contacted with organizations and institutions that have a huge interest in project´s result and will have an important role for assuring the proper dissemination of the final product.

Project partners would like to welcome you to this website that has been designed to highlight our objectives and the scientific activities of the groups of the consortium.

NEWS 01  


Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of menstrual cycle. Read more.    




10/01/2014. The partners of the project and the Scientific Advisory Board attended the Progress Meeting of the project in Madrid.  



October 7-10, 2013. ISCIII and SEPROX presented an oral communication and a poster in the AIDS Vaccine Conference. Read more.


Instituto de Salud Carlos III. 2013. All rights reserved

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305938.

Web Map  Legal AdviceAccesibility | Contact

cea unisr seprox biotech IscIII